Sir, just a clarification. So, the early teen kind of EBITDA growth we are talking about in FY’25, is it after considering the non-recurring expenses in complex hospital generic?
And secondly, on a quarter-on-quarter basis our interest cost has gone up, despite we have repaid a 1,000-odd crore kind of debt. So, just, is there some one-off to that? And secondly, how should we look the interest cost for FY’25?